Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily modified-release oxcarbazepine versus twice-daily Timox in partial onset epilepsy
2004-002260-25Phase 3Completed
- Sponsor
- Desitin Arzneimittel
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of timolol and oxcarbazepine in Focal Onset Epilepsy (2 arms), sponsored by Desitin Arzneimittel. Primary endpoints: Time-to-exit (failure time), Proportion of patients remaining seizure-free during randomized treatment and 1 more. Started Feb 2005; status: completed.
02
Drugs
timololoxcarbazepine
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2004-002260-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002260-25.